Raymond James Financial
LYEL icon

Raymond James Financial’s Lyell Immunopharma LYEL Stock Holding History

Raymond James Financial’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,900
Closed -$243K – 5381
2025
Q4 		$243K Buy
+7,900
New +$177K ﹤0.01% 4693
2025
Q3 		– Sell
-7,900
Closed -$69.8K – 5977
2025
Q2 		$69.8K Hold
7,900
– – ﹤0.01% 5040
2025
Q1 		$85K Buy
+7,900
New +$96.8K ﹤0.01% 4573

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James Financial's LYEL Position: Q1 2026 in Review

Raymond James Financial sold out of Lyell Immunopharma (LYEL) in Q1 2026, closing a stake of 7,900 shares — an estimated $243K sold.

Raymond James Financial first reported a position in LYEL in Q1 2025 and held it in 3 quarters. The position peaked at $243K in Q4 2025. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Raymond James Financial reported no remaining Lyell Immunopharma position as of Q1 2026 after selling out during the quarter.
  • Raymond James Financial sold 7,900 Lyell Immunopharma shares in Q1 2026, an estimated $243K.
  • Raymond James Financial first reported a position in Lyell Immunopharma in Q1 2025 and held it in 3 quarters.
  • Raymond James Financial's Lyell Immunopharma position peaked at $243K in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.